Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OCL010
MIFTS: 39

Ocular Hypotension

Categories: Eye diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Ocular Hypotension

About this section

MalaCards integrated aliases for Ocular Hypotension:

Name: Ocular Hypotension 12 44 15 73
Hypotony of Eye 12

Classifications:

MalaCards categories:
Anatomical: Eye diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:790
ICD10 33 H44.4 H44.40
ICD9CM 35 360.3 360.30
MeSH 44 D015814
UMLS 73 C0028841
Sources

Summaries for Ocular Hypotension

About this section
MalaCards based summary : Ocular Hypotension, also known as hypotony of eye, is related to primary eye hypotony and ocular hypertension, and has symptoms including eye manifestations An important gene associated with Ocular Hypotension is HTR2B (5-Hydroxytryptamine Receptor 2B), and among its related pathways/superpathways are Signaling by GPCR and DAG and IP3 signaling. The drugs Dexamethasone and Dorzolamide have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and brain.

Sources

Related Diseases for Ocular Hypotension

About this section

Diseases related to Ocular Hypotension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
# Related Disease Score Top Affiliating Genes
1 primary eye hypotony 11.1
2 ocular hypertension 10.1
3 open-angle glaucoma 10.0
4 macular retinal edema 9.9
5 resting heart rate, variation in 9.9 ADRB1 ADRB2
6 glaucoma, primary open angle 9.9
7 meningococcal infection 9.9 ADRB1 ADRB2
8 macular dystrophy, dominant cystoid 9.8
9 cataract 9.8
10 diabetic macular edema 9.8
11 aortic coarctation 9.8 ADRB1 ADRB2
12 orthostatic intolerance 9.7 ADRB1 ADRB2
13 uveitis 9.6
14 anterior uveitis 9.6
15 congestive heart failure 9.4 ADRB1 ADRB2

Comorbidity relations with Ocular Hypotension via Phenotypic Disease Network (PDN):


Glaucoma, Primary Open Angle Open-Angle Glaucoma

Graphical network of the top 20 diseases related to Ocular Hypotension:



Diseases related to Ocular Hypotension
Sources

Symptoms & Phenotypes for Ocular Hypotension

About this section

UMLS symptoms related to Ocular Hypotension:


eye manifestations
Sources

Drugs & Therapeutics for Ocular Hypotension

About this section

Drugs for Ocular Hypotension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
2
Dorzolamide Approved Phase 4,Phase 2 120279-96-1 3154 5284549
3
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
4
Timolol Approved Phase 4,Phase 2 26839-75-8 33624 5478
5
Carteolol Approved Phase 4 51781-06-7 2583
6
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
7 Dexamethasone acetate Phase 4,Phase 3 1177-87-3
8 glucocorticoids Phase 4,Phase 3
9
protease inhibitors Phase 4,Phase 3
10 Adrenergic Agents Phase 4,Phase 2,Not Applicable
11 Gastrointestinal Agents Phase 4,Phase 3
12 Neurotransmitter Agents Phase 4,Phase 2,Phase 1,Not Applicable
13 HIV Protease Inhibitors Phase 4,Phase 3
14 Hormone Antagonists Phase 4,Phase 3
15 Hormones Phase 4,Phase 3
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
17 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 1,Not Applicable
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Antiemetics Phase 4,Phase 3
20 Anti-Inflammatory Agents Phase 4,Phase 3
21 BB 1101 Phase 4,Phase 3
22 Autonomic Agents Phase 4,Phase 3
23 Antineoplastic Agents, Hormonal Phase 4,Phase 3
24 diuretics Phase 4
25 Adrenergic Antagonists Phase 4,Phase 2
26 Adrenergic beta-Antagonists Phase 4,Phase 2
27 Natriuretic Agents Phase 4
28 Sympatholytics Phase 4
29 Tetrahydrozoline Phase 4,Phase 1,Phase 2
30 Ophthalmic Solutions Phase 4,Phase 1,Phase 2
31 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2
32 Antihypertensive Agents Phase 4,Phase 2,Not Applicable
33 Anticonvulsants Phase 4
34 Carbonic Anhydrase Inhibitors Phase 4,Phase 2
35
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
36
Colchicine Approved Phase 3 64-86-8 6167 2833
37
Dalteparin Approved Phase 3 9005-49-6
38
Fluorouracil Approved Phase 3 51-21-8 3385
39
Ranibizumab Approved Phase 3,Not Applicable 347396-82-1 459903
40 calcium heparin Phase 3
41 Fibrinolytic Agents Phase 3
42 Heparin, Low-Molecular-Weight Phase 3
43 Anticoagulants Phase 3
44 Antirheumatic Agents Phase 3
45 Antimitotic Agents Phase 3
46 Calcium, Dietary Phase 3
47 Angiogenesis Inhibitors Phase 3,Not Applicable
48 Angiogenesis Modulating Agents Phase 3,Not Applicable
49
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
50 Analgesics Phase 1, Phase 2,Not Applicable

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients Completed NCT00972426 Phase 4 carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
2 COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy Completed NCT01228149 Phase 4 Trabeculectomy with preoperative Diamox/DexaEDO treatment;Trabeculectomy with preoperative Cosopt S treatment
3 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3 oral colchicine, dexamethasone, low molecular weight heparin, 5-FU;placebo
4 Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis Completed NCT02641457 Phase 3 Aflibercept;Ranibizumab
5 Aqueous Mushroom Extract and Intraocular Pressure Unknown status NCT01017068 Phase 1, Phase 2 OME;OME;OME;OME;OME;OME
6 COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED) Completed NCT00832377 Phase 2 timolol/dorzolamide combination
7 A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma Completed NCT01123785 Phase 1, Phase 2 INO-8875;Placebo
8 Dexmedetomidine as an Additive to Local Anaesthesia to Decrease Intraocular Pressure in Glaucoma Surgery Unknown status NCT02846090 Not Applicable Dexmedetomidine to reduce the IOP
9 Long-Term IOP Fluctuation and VF Progression After Triple Procedure Completed NCT00428740
10 PIO Laser Sclerectomy IOP SLT Sclerectomy Completed NCT01798732 Not Applicable
11 Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab Completed NCT00892398 Not Applicable ranibizumab
12 Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes Completed NCT00773136 Not Applicable Bimatoprost Suspension
13 Comparison of Phacotrabeculectomy and Trabeculectomy in the Treatment of Primary Angle-closure Glaucoma (PACG) Completed NCT01298635 Not Applicable
14 Selective Laser Trabeculoplasty After Failed Phacoemulsification With Eximer Laser Trabeculectomy Completed NCT02434250 Not Applicable
15 Primary Angle Closure Glaucoma and Aqueous Dynamics Completed NCT00719290 Not Applicable
16 An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments Completed NCT01735214 Prostaglandin Analogue -Containing IOP-Lowering Therapy
17 Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension Completed NCT01489670 bimatoprost 0.01% ophthalmic solution
18 Clinical Evaluation of CATS Tonometer Prism Recruiting NCT02990169 Not Applicable
19 Melatonin Decreases Eye Pressure in Normotensive Patients Recruiting NCT03193112 Agomelatine 25 MG Oral Tablet
20 Effect of Hyaluronidase on Intraocular Pressure Not yet recruiting NCT03266406 Not Applicable Hyaluronidase

Search NIH Clinical Center for Ocular Hypotension

Cochrane evidence based reviews: ocular hypotension

Sources

Genetic Tests for Ocular Hypotension

About this section
Sources

Anatomical Context for Ocular Hypotension

About this section

MalaCards organs/tissues related to Ocular Hypotension:

41
Eye, Endothelial, Brain
Sources

Publications for Ocular Hypotension

About this section

Articles related to Ocular Hypotension:

(show top 50) (show all 69)
# Title Authors Year
1
Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost. ( 28538979 )
2017
2
Repeated Intravitreous Ranibizumab Injections for Diabetic Macular Edema and the Risk of Sustained Elevation of Intraocular Pressure or the Need for Ocular Hypotensive Treatment. ( 25719991 )
2015
3
ADRB1 and ADBR2 gene polymorphisms and the ocular hypotensive response to topical betaxolol in healthy Mexican subjects. ( 24749907 )
2014
4
The ocular hypotensive effect of saffron extract in primary open angle glaucoma: a pilot study. ( 25319729 )
2014
5
Impact of ocular hypotensive lipids on clinically significant diabetic macular edema. ( 22267460 )
2012
6
Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. ( 21794845 )
2011
7
Morphine-induced ocular hypotension is modulated by nitric oxide and carbon monoxide: role of mu3 receptors. ( 20148660 )
2010
8
Ocular hypotension and hypotony in multibacillary leprosy patients; at diagnosis, during and after completion of multidrug therapy. ( 21434594 )
2010
9
Ocular hypotensive effects of topically administered agmatine in a chronic ocular hypertensive rat model. ( 19782071 )
2010
10
Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. ( 20426763 )
2010
11
Prolonged ocular hypotension: would ciliary tissue transplantation help. ( 19098698 )
2009
12
Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. ( 18992242 )
2009
13
Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow. ( 19234340 )
2009
14
Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: short-term, multicenter, prospective study. ( 19210139 )
2009
15
Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema? ( 18460537 )
2008
16
Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. ( 17565920 )
2007
17
Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. ( 17056362 )
2006
18
Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension. ( 17238805 )
2006
19
Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. ( 16968567 )
2006
20
Fadolmidine-induced ocular hypotension in normotensive rabbits. ( 15720782 )
2005
21
Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. ( 15216404 )
2004
22
PD128,907 induces ocular hypotension in rabbits: involvement of D2/D3 dopamine receptors and brain natriuretic peptide. ( 15006155 )
2004
23
Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. ( 15037111 )
2004
24
Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. ( 12676887 )
2003
25
New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. ( 14646172 )
2003
26
Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. ( 14733708 )
2003
27
Cystoid macular edema in the era of ocular hypotensive lipids. ( 11915838 )
2002
28
Cystoid macular edema associated with ocular hypotensive lipids. ( 11860980 )
2002
29
Ocular hypotension induced by electroacupuncture. ( 12222760 )
2002
30
2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: synthesis, carbonic anhydrase inhibition and evaluation in the rabbit. ( 10882008 )
2000
31
Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. ( 10614682 )
2000
32
8OH-DPAT-Induced ocular hypotension: sites and mechanisms of action. ( 10433858 )
1999
33
Mechanism of exercise-induced ocular hypotension. ( 10102302 )
1999
34
Ocular hypotension induced by intravitreally injected C-type natriuretic peptide. ( 9533834 )
1998
35
Lisuride acts at multiple sites to induce ocular hypotension and mydriasis. ( 9742290 )
1998
36
Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. ( 9851310 )
1998
37
Ocular hypotensive effect of topical ketanserin in timolol users. ( 9085107 )
1997
38
Potential mechanisms of moxonidine-induced ocular hypotension: role of norepinephrine. ( 9436152 )
1997
39
Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. ( 8921215 )
1996
40
Centrally mediated ocular hypotension: potential role of imidazoline receptors. ( 7677360 )
1995
41
Molecular characterization and ocular hypotensive properties of the prostanoid EP2 receptor. ( 8590276 )
1995
42
Evaluation of IBMX-enhanced ocular hypotension after adrenergic agonists in the rabbit eye. ( 7542619 )
1995
43
Correlates of acute exercise-induced ocular hypotension. ( 7928182 )
1994
44
Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. ( 7925603 )
1994
45
Ocular hypotension during short- and long-term hypocapnia. ( 19920601 )
1994
46
Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma. ( 8295364 )
1993
47
Long-term visual outcome of ocular hypotension after thermosclerostomy. ( 8488912 )
1993
48
PhXA34-induced ocular hypotension. ( 1463535 )
1992
49
Dexmedetomidine-induced ocular hypotension in rabbits with normal or elevated intraocular pressures. ( 1349879 )
1992
50
Reattachment of the detached ciliary body with suturing for treatment of contusional ocular hypotension. ( 1896179 )
1991
Sources

Variations for Ocular Hypotension

About this section
Sources

Expression for Ocular Hypotension

About this section
Search GEO for disease gene expression data for Ocular Hypotension.
Sources

Pathways for Ocular Hypotension

About this section

Pathways related to Ocular Hypotension according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 66
Show member pathways
 13.71 ADRB1 ADRB2 HTR2B PDE4B PDE4C PDE4D
2
DAG and IP3 signaling 66
Show member pathways
 12.47 ADRB1 ADRB2 PDE4B PDE4C PDE4D
3
Purine metabolism (KEGG) 22
Show member pathways
 12.29 PDE4B PDE4C PDE4D
4
Neuroscience 4
12.23 ADRB1 ADRB2 PDE4B
5
GABAergic synapse 37
Show member pathways
 12.2 PDE4B PDE4C PDE4D
6
ADP signalling through P2Y purinoceptor 12 66
Show member pathways
 12.12 ADRB2 PDE4B PDE4C PDE4D
7
Myometrial Relaxation and Contraction Pathways 1
Show member pathways
 12.05 ADRB1 ADRB2 PDE4B PDE4D
8
Calcium signaling pathway 37
Show member pathways
 11.92 ADRB1 ADRB2 HTR2B
9
Ca, cAMP and Lipid Signaling 4
11.74 ADRB1 ADRB2 PDE4B
10
Monoamine GPCRs 1
Show member pathways
 11.67 ADRB1 ADRB2 HTR2B
11
cAMP signaling pathway 37
Show member pathways
 11.66 ADRB1 ADRB2 PDE4B PDE4C PDE4D
12
Parathyroid hormone synthesis, secretion and action 37
11.61 PDE4B PDE4C PDE4D
13
Gap junction 37
11.53 ADRB1 HTR2B
14
Neurophysiological process Glutamate regulation of Dopamine D1A receptor signaling 22
Show member pathways
 11.5 PDE4B PDE4C PDE4D
15
Renin secretion 37
11.39 ADRB1 ADRB2
16
Antiarrhythmic Pathway, Pharmacodynamics 61
11.32 ADRB1 ADRB2
17
Regulation of lipolysis in adipocytes 37
11.29 ADRB1 ADRB2
18
G alpha (s) signalling events 66
11.19 ADRB1 ADRB2 PDE4B PDE4C PDE4D
19
Sympathetic Nerve Pathway (Neuroeffector Junction) 61
10.86 ADRB1 ADRB2
Sources

GO Terms for Ocular Hypotension

About this section

Cellular components related to Ocular Hypotension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated calcium channel complex GO:0005891 8.62 PDE4B PDE4D

Biological processes related to Ocular Hypotension according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.85 ADRB1 ADRB2 HTR2B PDE4B PDE4C PDE4D
2 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.6 ADRB1 ADRB2
3 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.59 ADRB1 ADRB2
4 neutrophil chemotaxis GO:0030593 9.58 PDE4B PDE4D
5 positive regulation of interferon-gamma production GO:0032729 9.58 PDE4B PDE4D
6 response to cold GO:0009409 9.57 ADRB1 ADRB2
7 activation of adenylate cyclase activity GO:0007190 9.56 ADRB1 ADRB2
8 brown fat cell differentiation GO:0050873 9.55 ADRB1 ADRB2
9 smooth muscle contraction GO:0006939 9.54 HTR2B PDE4D
10 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.52 ADRB1 ADRB2
11 positive regulation of interleukin-2 production GO:0032743 9.51 PDE4B PDE4D
12 cellular response to epinephrine stimulus GO:0071872 9.49 PDE4B PDE4D
13 negative regulation of multicellular organism growth GO:0040015 9.48 ADRB1 ADRB2
14 regulation of cardiac muscle cell contraction GO:0086004 9.46 PDE4B PDE4D
15 adrenergic receptor signaling pathway GO:0071875 9.43 ADRB2 PDE4D
16 G-protein coupled receptor signaling pathway GO:0007186 9.43 ADRB1 ADRB2 HTR2B PDE4B PDE4C PDE4D
17 diet induced thermogenesis GO:0002024 9.4 ADRB1 ADRB2
18 heat generation GO:0031649 9.32 ADRB1 ADRB2
19 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 9.26 ADRB1 ADRB2
20 negative regulation of relaxation of cardiac muscle GO:1901898 9.16 PDE4B PDE4D
21 cAMP catabolic process GO:0006198 8.8 PDE4B PDE4C PDE4D

Molecular functions related to Ocular Hypotension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer activity GO:0004871 9.61 ADRB1 ADRB2 HTR2B
2 ion channel binding GO:0044325 9.48 PDE4B PDE4D
3 drug binding GO:0008144 9.46 HTR2B PDE4D
4 cAMP binding GO:0030552 9.4 PDE4B PDE4D
5 3,5-cyclic-nucleotide phosphodiesterase activity GO:0004114 9.37 PDE4B PDE4D
6 adrenergic receptor activity GO:0004935 9.32 ADRB1 ADRB2
7 epinephrine binding GO:0051379 9.26 ADRB1 ADRB2
8 norepinephrine binding GO:0051380 9.16 ADRB1 ADRB2
9 phosphoric diester hydrolase activity GO:0008081 9.13 PDE4B PDE4C PDE4D
10 3,5-cyclic-AMP phosphodiesterase activity GO:0004115 8.8 PDE4B PDE4C PDE4D
Sources

Sources for Ocular Hypotension

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....